From Medscape Oncology

Coverage from the

San Antonio Breast Cancer Symposium (SABCS) 2017

December 05 - 09, 2017; San Antonio, Texas

December 05 - 09, 2017 San Antonio, Texas

SABCS Acupuncture Helps AI Pain; Insurers Should Cover, Say Trialists In a randomized controlled trial that was praised as well designed, acupuncture improved pain and stiffness among breast cancer patients taking aromatase inhibitors (AIs).
Medscape Medical News, December 8, 2017
SABCS Only 2 Years of Extended Anastrozole Needed in Breast Cancer After an initial 5 years of endocrine therapy in postmenopausal cancer, a further 2 years of the aromatase inhibitor is sufficient, instead of another 5 years, suggest new results.
Medscape Medical News, December 8, 2017
SABCS No Trastuzumab Benefit in HER2-Low Breast Cancer After All Despite previous analyses suggesting that adding trastuzumab to adjuvant chemotherapy may benefit patients with low HER2 expression, a new large trial shows no impact on outcomes.
Medscape Medical News, December 6, 2017

Meeting Highlights At A Glance

Top News From SABCS 2017: Slideshow Hot topics include new data on the optimum duration of adjuvant therapy, the efficacy of trastuzumab in HER2–negative tumors, and the advantages of dose-dense chemotherapy.

Conference News

SABCS ctDNA Testing 'Could Help Prevent Breast Cancer Relapses'
Medscape Medical News, December 18, 2017
SABCS GnRH Analogue Use Preserves Fertility During Chemotherapy
Medscape Medical News, December 18, 2017
SABCS Breast Pain Uncommon Symptom of Breast Cancer
Medscape Medical News, December 18, 2017
SABCS Simplified Surgery Reduces Lymphedema Risk After ALND
Medscape Medical News, December 18, 2017
SABCS Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
Medscape Medical News, December 11, 2017
SABCS Poor Screening Adherence May Worsen Breast Cancer Outcomes
Medscape Medical News, December 11, 2017
SABCS More Younger Women Opting for Bilateral Mastectomy
Medscape Medical News, December 11, 2017
SABCS Modest Weight Loss Cuts Postmenopausal Breast Cancer Risk
Medscape Medical News, December 11, 2017
SABCS First Data on Older Breast Cancer Pts on CDK4/6 Inhibitors
Medscape Medical News, December 11, 2017

SABCS Acupuncture Helps AI Pain; Insurers Should Cover, Say Trialists
Medscape Medical News, December 8, 2017
SABCS Statins May Up Breast Cancer-Specific and Overall Survival
Medscape Medical News, December 8, 2017
SABCS Only 2 Years of Extended Anastrozole Needed in Breast Cancer
Medscape Medical News, December 8, 2017
SABCS 'Intriguing': 9 Weeks of Trastuzumab for Breast Cancer
Medscape Medical News, December 8, 2017
SABCS Ribociclib Effective in Younger Breast Cancer Patients Too
Medscape Medical News, December 7, 2017
SABCS Pembro Boosts Treatment Impact in Advanced Breast Cancer
Medscape Medical News, December 7, 2017
SABCS Dose-Dense Chemotherapy Improves Outcomes in Breast Cancer
Medscape Medical News, December 6, 2017
SABCS No Trastuzumab Benefit in HER2-Low Breast Cancer After All
Medscape Medical News, December 6, 2017
SABCS What's Hot at SABCS 2017?
Medscape Medical News, November 28, 2017

Popular SABCS 2016 News

Aromatase Inhibitors: Is Cancer Benefit Worth Cardiac Risk? A new study of endothelial dysfunction in breast cancer patients prompts this question, especially in the context of long-term use.
Medscape Medical News, Dec 9, 2016
In HER2-Negative Breast Cancer, Brain Mets Are HER2-Positive 20% of Time Metastases to the brain do not necessarily have the same molecular signature as primary breast tumors. Some are 'wolves in sheep's clothing' and are targetable.
Medscape Medical News, Dec 15, 2016
Extending Adjuvant Endocrine Therapy: 3 Trials, Few Answers NSABP B-42, IDEAL and DATA trials dig down to small details.
Medscape Medical News, Dec 7, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Insights

'Cultural Change': Dialing Back the Discussion and Treatment of DCIS
E. Shelley Hwang, MD, MPH; Kathy D. Miller, MD
Late Recurrence in ER+ Breast Cancer: Banking on Biomarkers
Joseph A. Sparano, MD; Kathy D. Miller, MD
Will Immunotherapy Be a PANACEA for Breast Cancer?
Sherene Loi, MBBS (Hons), FRACP, PhD, FAHMS ; Kathy D. Miller, MD
For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Charles E. Geyer Jr, MD; Kathy D. Miller, MD
Does Breast Cancer Risk REACT to Celecoxib?
Charles Coombes, MD; Kathy D. Miller, MD
Hot Topics (and Hot Chilis): SABCS 2017
Kathy D. Miller, MD

Previous Coverage

Related Resource

Breast Cancer News & Perspectives